InMed Pharmaceuticals (INM) Share-based Compensation Growth (1y) (2020 - 2026)
InMed Pharmaceuticals (INM) Share-based Compensation Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 5.26% |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | -36.59% |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | -0.11% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | -49.74% |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -18.06% |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 23.11% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | -65.00% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.48 Mn | 1.24 Mn | - | -4.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 370.29% |
| Dec 31, 2025 | -9.09% |
| Sep 30, 2025 | 30.24% |
| Jun 30, 2025 | -263.30% |
| Mar 31, 2025 | -173.15% |
| Dec 31, 2024 | -226.80% |
| Sep 30, 2024 | -214.98% |
| Jun 30, 2024 | 109.42% |
| Mar 31, 2024 | 9.83% |
| Dec 31, 2023 | -74.14% |
| Sep 30, 2023 | -78.41% |
| Jun 30, 2023 | -333.67% |
| Mar 31, 2023 | -74.19% |
| Dec 31, 2022 | -67.11% |
| Sep 30, 2022 | 4.98% |
| Jun 30, 2022 | -19.91% |
| Mar 31, 2022 | -5.89% |
| Dec 31, 2021 | 122.26% |
| Sep 30, 2021 | 30.13% |
| Jun 30, 2021 | 41.48% |